Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537884 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A Phase 1 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04537884 is a Phase 1 study that has completed, run by Unity Biotechnology. The registered enrollment target is 19 participants.
The verdict
NCT04537884, a Phase 1 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
Interventions
- DRUG UBX1325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537884
The ClinicalTrials.gov registry entry for NCT04537884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UBX1325 is the first listed.
NCT04537884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537884 about?
NCT04537884 is a clinical study titled "Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration". A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
What is the current status of trial NCT04537884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-10-08. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT04537884?
The interventions under investigation include: UBX1325 (DRUG).
Who is sponsoring clinical trial NCT04537884?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.